To date, there is no evidence that TACE either before resection or liver transplantation helps to expand current selection criteria for patients with HCC or prevent recurrence.

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with ...

Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...

Chemoembolisation is a treatment directly into the liver. You have chemotherapy into the blood vessel ... It’s also called trans arterial chemoembolisation (TACE). You usually have this treatment if ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

Here is the most-viewed liver cancer content of 2024 ... EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC The EMERALD-1 trial results, presented ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

To date, there is no evidence that TACE pre-liver transplantation or resection helps to expand current selection criteria for patients with HCC, nor results in less recurrence after surgery.